BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30379729)

  • 1. A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study.
    Parillo M; Sapienza M; Arpaia F; Magnani F; Mallio CA; DʼAlessio P; Quattrocchi CC
    Invest Radiol; 2019 Apr; 54(4):191-197. PubMed ID: 30379729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadoxetate Disodium versus Gadoterate Meglumine: Quantitative Respiratory and Hemodynamic Metrics by Using Compressed-Sensing MRI.
    Glessgen CG; Moor M; Stieltjes B; Winkel DJ; Block TK; Merkle EM; Heye TJ; Boll DT
    Radiology; 2019 Nov; 293(2):317-326. PubMed ID: 31549944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
    McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
    Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.
    Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C
    Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
    Soyer P; Dohan A; Patkar D; Gottschalk A
    J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of gadoterate meglumine in children younger than 2 years of age.
    Farmakis SG; Hardy AK; Mahmoud SY; Wilson-Flewelling SA; Tao TY
    Pediatr Radiol; 2020 May; 50(6):855-862. PubMed ID: 32055917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative studies of the tolerability of gadodiamide, dimeglumine gadopentetate and meglumine gadoterate in MRI tests of the central nervous system].
    Chanalet S; Masson B; Boyer L; Laffont J; Bruneton JN
    J Radiol; 1995 Jul; 76(7):417-21. PubMed ID: 7473375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of inner ear MRI enhancement in patients with Meniere's disease after intravenous injection of gadobutrol, gadoterate meglumine, or gadodiamide.
    Xie J; Zhang W; Zhu J; Hui L; Li S; Zhang B
    Eur J Radiol; 2021 Jun; 139():109682. PubMed ID: 33813284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents.
    Robert P; Lehericy S; Grand S; Violas X; Fretellier N; Idée JM; Ballet S; Corot C
    Invest Radiol; 2015 Aug; 50(8):473-80. PubMed ID: 26107651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.
    Scala M; Koob M; de Buttet S; Bourrinet P; Felices M; Jurkiewicz E
    Invest Radiol; 2018 Feb; 53(2):70-79. PubMed ID: 28906338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children.
    Forbes-Amrhein MM; Dillman JR; Trout AT; Koch BL; Dickerson JM; Giordano RM; Towbin AJ
    Invest Radiol; 2018 May; 53(5):313-318. PubMed ID: 29337841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis.
    Haylor J; Schroeder J; Wagner B; Nutter F; Jestin G; Idée JM; Morcos S
    Radiology; 2012 Apr; 263(1):107-16. PubMed ID: 22344402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Perinatal Gadolinium-Based Contrast Agents on Adult Mice Behavior.
    Khairinisa MA; Takatsuru Y; Amano I; Erdene K; Nakajima T; Kameo S; Koyama H; Tsushima Y; Koibuchi N
    Invest Radiol; 2018 Feb; 53(2):110-118. PubMed ID: 28915162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Speciation Analysis of Residual Gadolinium in Deep Cerebellar Nuclei in Rats Repeatedly Administered With Gadoterate Meglumine or Gadodiamide.
    Strzeminska I; Factor C; Jimenez-Lamana J; Lacomme S; Subirana MA; Le Coustumer P; Schaumlöffel D; Robert P; Szpunar J; Corot C; Lobinski R
    Invest Radiol; 2022 May; 57(5):283-292. PubMed ID: 35066532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
    Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
    Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30,000 MR examinations.
    De Ridder F; De Maeseneer M; Stadnik T; Luypaert R; Osteaux M
    JBR-BTR; 2001 Aug; 84(4):150-2. PubMed ID: 11688727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
    McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
    J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
    de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
    Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone and soft-tissue disease.
    Colafati GS; Rossi E; Carducci C; Piga S; Voicu IP; Mastronuzzi A; Tomà P
    Pediatr Radiol; 2018 Nov; 48(12):1724-1735. PubMed ID: 30046901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study.
    Chang DH; Pracros JP
    Acta Radiol; 2019 Nov; 60(11):1450-1456. PubMed ID: 31027425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.